GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly
Information source: Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Acute Myeloid Leukemia
Intervention: Active comparator (no fludarabine) (Drug); Experimental (fludarabine) (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS Official(s) and/or principal investigator(s): Francis WITZ, MD, Principal Investigator, Affiliation: Groupe Ouest Est d'Etude des LeucĂ©mies et Autres Maladies du Sang GOELAMS
Summary
In this study, patients were randomly assigned to either receive fludarabine or not (20
mg/m2/d) in addition to induction chemotherapy, consolidation chemotherapy and the 3
subsequent re-induction courses during maintenance.
Clinical Details
Official title: A Randomized Study of Fludarabine in Part of Induction and Postremission Treatment for de Novo Acute Myeloid Leukaemia in Elderly Patients
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Event-free survival (EFS)
Secondary outcome: evaluation of the CR rate, remission duration disease-free survival (DFS) overall survival (OS),
Detailed description:
Eligibility for enrollment in the study was limited to patients aged 60 to 75 years old with
previously untreated de novo AML as defined morphologically by the French-American-British
(FAB) classification with the exception of M3 and M7 subtypes. 10,11 The bone marrow aspirate
had to show at least 30 percent of nonerythroid blast cells. Patients were not eligible if
they had a performance status before diagnosis of 2 or more according to the World Health
Organization (WHO) grading system, congestive heart failure or abnormal left ventricular
ejection fraction, severe hepatic or renal disturbances if not related to leukemia (hepatic
enzymes levels over four times the normal values, serum bilirubin over 35 micromol/L,
creatinine over 150 micromol/L). Patients with previous unexplained cytopenia were eligible
for the study. Conversely, patients with a history of documented myelodysplastic or
myeloproliferative syndrome or previously treated with chemotherapy or radiation could not
enter the study. The study received in June 1996 approval from the ethics' board of the
Nancy Hospital and written informed consent was given by all eligible patients before
entering the study, in accordance with the Declaration of Helsinki. The enrollment period
was open from November 1996 to April 2000.
Eligibility
Minimum age: 60 Years.
Maximum age: 75 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients aged 60 to 75 years old
- untreated de novo AML
- performance status less than 2
Exclusion Criteria:
- performance status more than 2
- congestive heart failure or abnormal left ventricular ejection fraction
- severe hepatic or renal disturbances
- history of documented myelodysplastic or myeloproliferative syndrome
- patients previously treated with chemotherapy or radiation
Locations and Contacts
GOELAMS, Tours 37000, France
Additional Information
Goelams internet site
Starting date: June 1996
Last updated: June 19, 2009
|